Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Albireo Pharma Inc (NQ: ALBO )

30.80 USD -0.95 (-2.99%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 23, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 395,597
Open 31.43
Bid (Size) 30.90 (3)
Ask (Size) 31.10 (2)
Prev. Close 31.75
Today's Range 30.37 - 32.05
52wk Range 22.78 - 49.00
Shares Outstanding 19,194,729
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
MULTIMEDIA UPDATE - Albireo Announces FDA Approval of Bylvay™ (odevixibat), the First Drug Treatment for Patients With Progressive Familial Intrahepatic Cholestasis (PFIC)
From GlobeNewswire News Releases
Albireo Announces FDA Approval of Bylvay™ (odevixibat), the First Drug Treatment for Patients With Progressive Familial Intrahepatic Cholestasis (PFIC)
From GlobeNewswire News Releases

Performance

YTD
-16.71%
-16.71%
1 Month
-16.46%
-16.46%
3 Month
-3.30%
-3.30%
6 Month
-15.34%
-15.34%
1 Year
+21.98%
+21.98%

More News

Read More
Albireo Receives European Marketing Authorization of Bylvay™ (odevixibat), the First Drug Treatment for Progressive Familial Intrahepatic Cholestasis (PFIC)
From GlobeNewswire News Releases
Albireo to Present at the William Blair Biotech Focus Conference 2021
From GlobeNewswire News Releases
Albireo to Present at Piper Sandler’s Virtual EASL Takeaway Day
From GlobeNewswire News Releases
Albireo Announces Expanded Phase 3 Data on Bylvay™ (odevixibat) and A3907 at Upcoming EASL International Liver Congress
From GlobeNewswire News Releases
Albireo to Showcase New Data at the EASL International Liver Congress™ 2021
From GlobeNewswire News Releases
New Phase 3 Data at WCPGHAN Show Long-Term Safety, Tolerability, and Treatment Benefits of Bylvay™ (odevixibat) in PFIC
From GlobeNewswire News Releases
Albireo's Rare Liver Disease Drug Bylvay Scores Back To Back Approvals In Europe, US
Tags Briefs News Pediatrics
From Benzinga
Albireo to Present at Upcoming Jefferies and William Blair Virtual Investor Conferences
From GlobeNewswire News Releases
Albireo's Bylvay Scores European Nod For Rare Pediatric Liver Disease
Tags Biotech Liver Disease Small Cap
From Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.